NASDAQ:CMRX

Delisted

Chimerix Stock News

Healthcare > Biotechnology

Buy CMRX

*Your capital is at risk

$8.54

+0 (+0%)

At Close: Jul 18, 2025

RNG, OVID, WLL and AVYA among notable after hours movers

12:00am, Thursday, 03'rd Oct 2019

Chimerix to Present at —…–9 Cantor Global Healthcare Conference

12:00am, Friday, 27'th Sep 2019

Chimerix Announces Co. Is Finalizing Animal Studies Of Brincidofovir As Smallpox Medical Countermeasure For Planned NDA

12:38pm, Thursday, 08'th Aug 2019

Chimerix Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $1.438M Beat $1.15M Estimate; Phase 3 Trial Of Cx-01 In Front-Line Acute Myeloid Leukemia Planned To Initiate In Mid 2020

12:38pm, Thursday, 08'th Aug 2019

Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates

12:00am, Thursday, 08'th Aug 2019

Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

12:00am, Wednesday, 07'th Aug 2019

Chimerix Announces Exclusive Worldwide License Of Phase 3 Ready CX-01 For Development In Acute Myeloid Leukemia

12:00am, Wednesday, 31'st Jul 2019

Chimerix terminates patent license deal with UC

12:00am, Wednesday, 03'rd Jul 2019

Week 27 Breakout Forecast: Short-Term Picks To Give You An Edge

12:00am, Sunday, 30'th Jun 2019

Week 26 Breakout Forecast: The Friday Anomaly Gives Way To The Pre-FOMC Drift

12:00am, Tuesday, 25'th Jun 2019

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

12:00am, Saturday, 18'th May 2019

Novavax leads healthcare gainers; Genetic Technologies and InspireMD among losers

12:00am, Tuesday, 14'th May 2019

Chimerix Stock News

RNG, OVID, WLL and AVYA among notable after hours movers

Chimerix to Present at —…–9 Cantor Global Healthcare Conference

Chimerix Announces Co. Is Finalizing Animal Studies Of Brincidofovir As Smallpox Medical Countermeasure For Planned NDA

Chimerix Q2 EPS $(0.35) Beats $(0.37) Estimate, Sales $1.438M Beat $1.15M Estimate; Phase 3 Trial Of Cx-01 In Front-Line Acute Myeloid Leukemia Planned To Initiate In Mid 2020

Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates

Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Chimerix Announces Exclusive Worldwide License Of Phase 3 Ready CX-01 For Development In Acute Myeloid Leukemia

Chimerix terminates patent license deal with UC

Week 27 Breakout Forecast: Short-Term Picks To Give You An Edge

Week 26 Breakout Forecast: The Friday Anomaly Gives Way To The Pre-FOMC Drift

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

Novavax leads healthcare gainers; Genetic Technologies and InspireMD among losers

Chimerix Restructuring To Reduce Workforce By More Than 50%, Maintaining Key Capabilities And Preserving Capital For New Programs

Will Chimerix (CMRX) Report Negative Q1 Earnings? What You Should Know

ContraVir And CRV431 In NASH: An Update

Top Fintech Company